—

Glaukos Corp (GKOS) — the peer cohort

As of 2026-10-12 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Glaukos Corp ranks 11 of 11 in its cohort on the Closelooknet composite (48/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
GKOS Glaukos Corp 48 81 24 18 info 12.3%
DXCM DexCom Inc 66 85 80 35 bull 9.2%
GMED Globus Medical 60 32 64 57 bear 26.4%
SECT-B.ST Sectra AB (publ) 60 83 66 11 bull 6.7%
SNN Smith & Nephew SNATS Inc 56 24 55 73 warn 25.1%
SOON.SW Sonova H Ag 56 92 72 50 bull 0.3%
CEVI.ST CellaVision AB 55 73 69 29 watch 13.9%
HALO Halozyme Therapeutics Inc 74 94 94 48 ok 4.9%
ONC BeiGene, Ltd. 63 76 62 30 info 9%
MEDP Medpace Holdings Inc 63 85 74 28 ok 8.5%
ARGX argenx NV ADR 62 50 74 29 info 24.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-12

Quick answers

Who are Glaukos Corp's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: DexCom Inc (DXCM), Globus Medical (GMED), Sectra AB (publ) (SECT-B.ST), Smith & Nephew SNATS Inc (SNN), Sonova H Ag (SOON.SW), CellaVision AB (CEVI.ST), Halozyme Therapeutics Inc (HALO), BeiGene, Ltd. (ONC) and others.

How does GKOS score against its peers?

Glaukos Corp's composite reads 48/100, ranking 11 of 11 in its cohort as of 2026-10-12; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.